Skip to main content
Donate

Evaluation of IGF-2 and IGF-2 Receptor Ligand (L1) in a Rat Model of Angelman Syndrome on the EEG and Seizure Phenotype

$212,730 2019 FT2019-003: 2019-2020

Evaluation of IGF-2 and IGF-2 Receptor Ligand (L1) in a Rat Model of Angelman Syndrome on the EEG and Seizure Phenotype

Previous studies by the Alberini lab at NYU show that IGF-2 and L1 rescue neurological symptoms in a mouse model of Angelman syndrome. Preliminary analyses of the AS rat model indicate that EEG and seizure phenotypes are largely similar to those observed in the AS mouse model and AS patients. The aims of this study are to determine whether IGF-2 or L1 alters EEG activity in the AS rat model, evaluate the effect of IGF-2 or L1 on seizure threshold in AS rat model, determine effect of IGF-2 or L1 on sleep and circadian cycling in AS rat model, and assess whether IGF2 or L1 affects behavioral related EEG activity in AS rat model.

Principle Investigator

Anne Anderson, MD

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.